PharmaVentures appoints senior director in Transactions

Ping Shek will work on key M&A accounts in healthcare

Corporate advisory firm PharmaVentures, based in Oxford, UK, has appointed Ping Shek as senior director in the Transactions division of Corporate Advisory. He will work on key M&A and divestment accounts in the healthcare business sector.

Shek is a physics graduate from Oxford and has an MBA from the London Business School. He has previously worked with investment bankers Morgan Stanley International, Lazard Brothers, JP Morgan, Monitor Group and the Anglo Chinese Group.

Commenting on the appointment, Fintan Walton, PharmaVentures’ chief executive, said: ‘Our Transactions division is currently working with a number of key companies in the life sciences sector, providing a comprehensive M&A and asset divestment service and has recently celebrated successes for a number of clients including UCB, Sanofi, Helsinn and Dow Chemical. Our client portfolio will benefit from this key appointment to the team.’

You may also like

Media

Licensing deals fall as r&d expenditure is cut

But M&A activity remained robust in 2011, says PharmaVentures
Media

Curia receives 2024 CDMO leadership award

Curia recognised for its service in the CDMO industry
Media

Biovian and 3P Biopharmaceuticals join forces to create 3PBIOVIAN

Biovian and 3P Biopharmaceuticals, two leading biologics CDMOs, announce their combination to establish a new pan-European leader in their field
Media

Royal Society of Chemistry and TIB co-create next generation Open Access consortium model

The agreement delivers shared goals of equity for institutions, a community approach and universal open access for authors
Media

Thermo Fisher launches industry’s first off-the-shelf solution to streamline and automate cell therapy manufacturing

Gibco CTS Cellmation Software digitally connects instruments from across Thermo Fisher’s cell therapy portfolio to streamline and automate manufacturing
Media

Two new appointed members have joined the RSC’s Board of Trustees

The dual appointment will add invaluable commercial acumen and project leadership experience
Media

India pharma growth expectations in 2024 are the highest globally, say CPHI & PMEC India

More than 60% of the executives here are "highly positive" about 2024 — the highest of any country
Subscribe now